Use of bioidentical compounded hormones for menopausal concerns: Cross-sectional survey in an academic menopause center

Journal of Women's Health

Volumn 20, Issue 4, 2011, Pages 559-565

  Iftikhar, Salma ^a   Shuster, Lynne T ^a   Johnson, Ruth E ^a   Jenkins, Sarah M ^a   Wahner Roedler, Dietlind L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PRASTERONE; TESTOSTERONE;

ADULT; ANXIETY; ARTICLE; BIOIDENTICAL COMPOUNDED HORMONE THERAPY; BLOOD LEVEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; FATIGUE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MEMORY; MENOPAUSAL SYNDROME; MENOPAUSE; MONITORING; NIGHT SWEAT; PATIENT SATISFACTION; PRIORITY JOURNAL; SALIVA LEVEL; SEXUAL DYSFUNCTION; SLEEP DISORDER; VAGINAL DRYNESS;

ACADEMIC MEDICAL CENTERS; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; MINNESOTA; PATIENT SATISFACTION;

EID: 79954502698     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2009.1915     Document Type: Article

References (35)

1. North American Menopause Society. Estrogen and proges-togen use in postmenopausal women: 2010 position state-ment of The North American Menopause Society. Menopause 2010;17:242-255.
2. U.S. Department of Health and Human Services, U.S. Food and Drug Administration FDA takes action against compounded menopause hormone therapy drugs. Silver Spring, MD: U.S. Food and Drug Administration, 2008. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008 ucm116832.htm Accessed January 25, 2009.
3. U.S. Department of Health and Human Services, U.S. Food and Drug Administration. Petition response. 2008. Available at www.fda.gov/ohrms/dockets/ dockets/05p0411/05p-0411-let0003-vol198.pdf Accessed July 9, 2010.
4. Boothby LA, Doering PL, Kipersztok S. Bioidentical hor-mone therapy: A review. Menopause 2004;11:356-367.
5. Cirigliano M. Bioidentical hormone therapy: A review of the evidence. J Womens Health 2007;16:600-631. (Pubitemid 47093906)
6. Sites CK. Bioidentical hormones for menopausal therapy. Womens Health (Lond) 2008;4:163-171. (Pubitemid 351513636)
7. Council of the convention section on the quality of com-pounded medicine. White paper: A model system to pro-mote access to good quality compounded medicines. 2009. Available at www.thehill.com/resources/white-papers/quality-in- compounded-medicines/67393-a-model-system-to-promote-access-to-good-quality- compounded-medicines/Accessed May 26, 2010.
8. Council of the convention section on the quality of com-pounded medicine. White paper: USP's role in setting en-forceable quality standards for medicines. 2009. Available at www.usp.org/pdf/EN/members/qualityMedicines.pdf Accessed May 26, 2010.
9. International Academy of Compound Pharmacists (IACP). The truth about bioidentical hormones. Available at www.iacprx.org/site/DocServer/BHRT-Myth- Fact.pdf?docID=2882 Accessed July 9, 2010.
10. International Academy of Compound Pharmacists (IACP). Pharmacy compounding is a well-regulated, safe and legal practice. Available at www.iacprx.org/site/DocServer/CCH08Resources-Regulation-of-Compounding-final. pdf? docID=3541 Accessed July 9, 2010.
11. Parker-Pope T. Health journal: Popular menopause hor-mones come under scrutiny. Post-gazette NOW, 2005. Available at www.post-gazette.com/pg/05298/ 594620.stm #ixzz0JT1dICxZ&D Accessed January 25, 2009.
12. Bioidentical hormones: Sound science or bad medicine? Hearing before the U.S. Senate Special Committee on Aging, 110th Congress, 1st Session (April 19, 2007). Available at frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110- senate-hearings&docid=f:37150.pdf Accessed June 25, 2009.
13. Rossouw JE, Anderson GL, Prentice RL, et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
14. Holtorf K. The bioidentical hormone debate: Are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hor-mone replacement therapy? Postgrad Med 2009;121:73-85.
15. Hersh AL, Stefanick ML, Stafford RS. National use of post-menopausal hormone therapy: Annual trends and response to recent evidence. JAMA 2004;291:47-53. (Pubitemid 38040534)
16. Statement of Loyd V. Allen Jr, PhD, RPh, Editor-in-Chief, International Journal of Pharmaceutical Compounding: Hearing before the U.S. Senate Special Committee on Aging, 110th Congress, 1st Session (April 19, 2007). Available at aging.senate.gov/events/hr171la.pdf Accessed June 25, 2009.
17. Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with "bioidentical" hormone replacement therapy. Med J Aust 2007;187:244-245.
18. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: A case-control study. Breast Cancer Res 2006;8:R11.
19. Boothby LA, Doering PL. Bioidentical hormone therapy: A panacea that lacks supportive evidence. Curr Opin Obstet Gynecol 2008;20:400-407.
20. Adams C, Cannell S. Women's beliefs about "natural" hor-mones and naturalhormone replacement therapy. Menopause 2001;8:433-440. (Pubitemid 33111580)
21. Barnes PM, Bloom B, Nahin RL. Complementary and alter-native medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008;12:1-23.
22. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
23. Erratum in JAMA 1995;274:1676.
24. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111. (Pubitemid 350179584)
25. Erratum in Breast Cancer Res Treat 2008;107:307-308.
26. Brinton RD, Thompson RF, Foy MR, et al. Progesterone re-ceptors: Form and function in brain. Front Neuroendocrinol 2008;29:313-339.
27. Archer DF. Progestogens: Effects on clinical and biochemical parameters in postmenopausal women. Menopause 2005;12: 484-487. (Pubitemid 41362070)
28. Santen RJ, Allred DC, Ardoin SP, et al., Endocrine Society. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(Suppl 1): s1-s66.
29. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ 2010;340:c2519.
30. Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697-3710. (Pubitemid 44536831)
31. Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric 2008;11: 181-191.
32. Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of pro-gesterone from transdermal creams in postmenopausal women. Maturitas 2002;41:1-6. (Pubitemid 34102384)
33. O'Leary P, Feddema P, Chan K, Taranto M, Smith M, Evans S. Salivary, but not serum or urinary, levels of progesterone are elevated after topical application of progesterone cream to pre-and postmenopausal women. Clin Endocrinol (Oxf) 2000;53:615-620.
34. The North American Menopause Society. NAMS confirms its support of FDA warning about custom-compounded bioidentical hormone therapy. Cleveland, OH: The North American Menopause Society, 2009. Available at www.menopause.org/media/ pr0209Bioshow.pdf Accessed June 25, 2009.
35. National Women's Health Resource Center. Women's health updates: Hormone therapy options: Bioidentical hormones. Red Bank, NJ: National Women's Health Resource Center, 2005.